Therapeutics Initiative A SHORT HISTORY
|
|
- Sophia Heath
- 5 years ago
- Views:
Transcription
1 Therapeutics Initiative A SHORT HISTORY
2 Therapeutics Initiative, 1994 (10 individuals) Mission: To provide physicians and pharmacists with up-to-date, evidence-based, practical information on prescription drug therapy. First Task: To become expert in assessing evidence from clinical trials of new drugs in Canada, and to provide the evidence to Pharmacare. First policy decision: No conflicts of interest were allowed.
3 What happened? We became expert in critical appraisal and assessment of evidence from clinical trials. We got involved in the Cochrane Collaboration and learned their methodology. We hired experts in Health Technology Assessment and Systematic Review.
4 Interventions implemented Therapeutics Letter 6 times per year posted on website and mailed to physicians and pharmacists in BC. Letters provided the best available evidence about the benefits and harms of drugs and drug classes. Letters provided drug cost information.
5 What did the clinicians think about the Letter? ANSWERED BY REGULAR SURVEYS
6
7 What was the impact on prescribing of the first 20 Letters? ANSWERED USING A RANDOMISED CONTROLLED TRIAL.
8 Effect of periodic letters on evidence-based drug therapy on prescribing behaviour: a randomized trial Dormuth CR, Maclure M, Bassett K, Jauca C, Whiteside C, Wright JM (CMAJ 2004; 171(9): ) The Therapeutics Initiative is funded by a grant from the Government of British Columbia 8
9 Methods Physicians: -Study population included 499 physicians from 24 local health areas in British Columbia, Canada Communities: -Paired according to the number of physicians. -One in each pair was randomly assigned to the intervention group and the other to the control group Source databases: -Physician service records and drug claims records from the British Columbia Ministry of Health 9
10 Methods Analyses: -Incidence of newly treated patients was measured -For each drug group studied, patients were classified as being newly treated if none of the drugs in the group were dispensed to them in the previous year. 10
11 Results Table: Characteristics of treatment and control physicians Treatment Control Characteristic Group (n=258) Group (n=241) Physicians: % General Practitioners Average age % Males/Females 89/11 83/17 Patients: Average age 35.5 (75.2) 35.0 (75.3) % Males/Females/Unknown 46/52/2 (44/52/4) 46/52/2 (44/52/4) Avg. no. visits / MD 6402 (1322) 6660 (1340) Results in brackets are for subset of patient population 65 and older. 11
12 Source: Dormuth CR, Maclure, et al. CMAJ 2004; 171(9):
13 Interpretation Printed letters distributed as a series regularly from a trusted source has a modest desirable impact on prescribing to new patients. Further work needs to be done to determine the sustainability of prescribing changes, and to determine what aspects of printed letters elicit prescribing changes 13
14 What policies were implemented? Outcomes based coverage. Funding of new drugs was based on the best available evidence. A new drug only became a full benefit if it represented a therapeutic advantage or a cost advantage over appropriate alternatives.
15 Examples of drug classes affected by this policy Non-steroidal anti-inflammatory drugs (Cox-2 selective NSAIDs). Oral hypoglycemic drugs (glitazones and others). Cholinesterase inhibitors for Alzheimers Disease.
16 What other policies were implemented? Reference based pricing of equivalent drugs within a drug class. Restricted access based on special authority criteria. Therapeutic substitution
17 Reference based pricing January 1, 1997 least expensive ACE inhibitors fully covered (captopril, quinapril, ramipril). More expensive ACE inhibitors covered up to a maximum of $27 per month (benazepril, cilazapril, enalapril, fosinopril, lisinopril). Patients on more expensive ACEI could pay the difference or switch.
18 Outcomes of reference pricing for angiotensin-convertingenzyme inhibitors SCHNEEWEISS S, WALKER AM, GLYNN RJ, MACLURE M, DORMUTH C, SOUMERAI SB. N ENGL J MED 2002;346:822-9
19 No increase in Emergency Hospitalizations due to RP 19 Schneeweiss et al. N Engl J Med 2002
20 Pharmacy savings in prevalent ACEI users 20 $60 Projected prepolicy trend $50 $40 $30 $20 $10 $0 Apr-96 May-96 Jun-96 Jul-96 Aug-96 Sep-96 Oct-96 Nov-96 Dec-96 Jan-97 Feb-97 Mar-97 Apr-97 May-97 Jun-97 Jul-97 Aug-97 Sep-97 Oct-97 Nov-97 Dec-97 Jan-98 Feb-98 Mar-98 Apr-98 Average monthly anti-hypertensives ingredient expenditures per patient 12 month savings: $6,700,000 Month Schneeweiss et al. J Can Med Assoc, 2002
21 Reference pricing for ACEI conclusions 18% of patients switched to lower cost alternative. Not associated with changes in physician visits, hospitalizations or mortality. Cost savings to drug funder of approximately $6 million per year.
22 What was the impact of these policies on drug utilization and costs?
23
24 Canadian Rx atlas 2007 Overall per capita spending by province
25 Canadian Rx atlas 2007 Non-steroidal anti-inflammatory drugs
26 Canadian Rx atlas 2007 Oral diabetes drugs
27 Canadian Rx Atlas 2007 Cholinesterase inhibitors
28 How much did BC save on prescription drug costs in 2007? If BC's drug utilization was the same as the Canadian average in 2007, total spending in our province would have been $701 million higher. $455 million of this saving was due to BC residents purchasing fewer drugs, while $208 million reflects the savings from choosing lower-cost treatment options.
29 Why were the policies successful? The TI did not allow any conflicts of interest. Establishing questions for review was an iterative process. Drug Assessment Working Group (DAWG) followed Cochrane methodology. DAWG improved critical appraisal skills and assessing risk of bias over time.
30 Why were the policies successful? Researchers were contracted to independently evaluate the impact on drug utilization and health outcomes. Ministry of Health personnel remained committed to outcomes based coverage and other policies despite political pressures.
31 What did the TI team learn? All drugs with any effect have both benefits and harms. Drugs are less effective than what we thought was true. Drugs are more harmful than what we thought was true. In many instances we were shocked that Health Canada had approved the drugs for market. In most instances drugs are marketed without knowing that the benefits outweigh the harms in many if not all the clinical settings where they are used.
32 Who were happy about this program? Ministry of Health Taxpayers Most doctors PATIENTS
33 Who were unhappy about the program? The elephants. Some doctors (specialists) who are friends of the elephants.
34 What should of happened? Expansion of the reference based program to new classes of drugs eg. Statins. Continued development of the international reputation of BC as a drug policy innovator. Increased funding to the Therapeutics Intiative to increase the expertise and ensure the long-term future.
35 What Happened? In October 2007 a Pharmaceutical Task Force was announced by BC Health Minister with the following objectives: 1. Identify and strengthen patient care and choice; 2. Optimize the decision-making process for what drugs are covered under PharmaCare; 3. Improve the effectiveness of the Common Drug Review process; 4. Enhance the effectiveness, transparency and future role of the Therapeutics Initiative.
36 Nine member Pharmaceutical task force Chair, Don Avison, President of the University Presidents Council. Board member LifeSciences BC. Robert Sindelar, Dean, Faculty of Pharmaceutical Sciences, UBC. Board member LifeSciences BC. Russell Williams, president of Canada s Researchbased Pharmaceutical Companies (Rx&D). Susan Paish, Q.C., chief executive officer, Pharmasave Drugs (National) Ltd. David M. Hall, chief compliance officer and senior vice president of Community Relations, Angiotech Pharmaceuticals. 2 Ministry of Health members. 2 others.
37 PSF recommendations for TI April 2008 #4 The Ministry of Health should establish a new Drug Review Resource Committee to carry out the drug submission review role currently performed by the Therapeutics Initiative. #12 Subject to Recommendation #4, if the Therapeutics Initiative is maintained, action must be taken in the following areas: improve the governance, membership and accountability standards; renew and revitalize the panel of expert reviewers;
38 THE MINISTER OF HEALTH ACCEPTED ALL THE RECOMMENDATIONS OF THE PHARMACEUTICAL TASK FORCE AND SET UP A MECHANISM FOR THEIR IMPLEMENTATION.
39 Academic review of TI 3 member external panel reviewed the TI over 2 days in October Validated the roles and activities of the TI in drug assessment, pharmacoepidemiology and education. Recommendations: Stable funding must be ensured. The present funding is inadequate. 3 new permanent University F-slots should be established.
40 What has happened? The TI s advisory role to the BC Ministry of Health has been severely curtailed. The TI s funding from the BC Ministry of Health has been reduced to $550,000 per year for the Therapeutics Letter and Pharmacoepidemiology work. The University has not created any new positions in response to the Academic Review recommendations.
41 What has happened? In November 2009, Don Avison confirmed that he was recently appointed as the Canadian representative on Pfizer s Global International Advisory Board. He did not respond to an asking what he will be paid. Don Avison received a Leadership award from LifeSciences BC for his role as Chair of the Pharmaceutical Task Force.
42 What has happened? In the spring of 2012 an investigation into data access is initiated by the BC Ministry of Health. In June, 2012, TI data access is cut off as a result of the investigation. In October, 2012, TI funding is suspended by the Ministry as a result of the investigation. In October, 2013, the Ministry of Health announces that TI funding and data access will be restored.
43 What is wrong with the prescription drug system? The elephants (Brand Name drug companies) are too wealthy and powerful. Recommended reading: The Corporation: The pathological pursuit of profit and power by Joel Bakan (UBC Professor). It is not the fault of the corporations. Governments established the system that got us here and must bring in regulations to correct it.
44 Ways to improve the system. Support present independent groups investigating the benefits and harms of prescription drugs. New money for new groups and to support networking between groups internationally. Continue to educate prescribers and patients about the benefits and harms of prescription drugs.
45
46 Questions????
Spring Understanding the potential of generic substitution
Spring 2014 Understanding the potential of generic substitution Understanding the potential of generic substitution Generic pricing reforms and the availability of generics for blockbuster drugs coming
More informationOsteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage
Osteoporos Int (212) 23:1475 148 DOI 1.17/s198-11-1771-2 ORIGINAL ARTICLE Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage S. M. Cadarette & G. Carney
More informationMonitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH
1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives
More informationPublished by the Pharmaceutical Services Division to provide information for British Columbia s health care providers
Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Keeping the Lines Clear... 1 Newsletter Notification Service... 1 Special
More informationManufacturer Comments Clinical Evidence Review Report and Supplemental Update and Pharmacoeconomic Review Report
Manufacturer Comments Clinical Evidence Review Report and Supplemental Update and Pharmacoeconomic Review Report Drug Product Generic name (Brand name) Manufacturer (Distributor if applicable) Alzheimer
More informationGuide to the Modernized Reference Drug Program
Guide to the Modernized Reference Drug Program For prescribers and pharmacists Medical Beneficiary and Pharmaceutical Services Division June 1, 2016 Contents 1 Introduction 1 2 About this Guide 2 3 About
More informationModernized Reference Drug Program
Modernized Reference Drug Program Monitoring Report For the period ending May 31, 2017 Issued: November 2017 Published by: Pharmaceutical Services Division and Health Sector Information, Analysis and Reporting
More informationThe Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England
The Infection Control Doctor and Clostridium difficile infection Dr David R Jenkins University Hospitals of Leicester NHS Trust, England 250 200 150 100 50 0 Monthly cases of Clostridium difficile (UHL
More informationVIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC
1 VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC Virginia Association of Counties November 14, 2016 The Honorable William A. Hazel, Jr., M.D. Secretary of Health and Human Resources 1999 - Estimated drug
More informationPresenter Disclosure Information
Presenter Disclosure Information Soko Setoguchi, MD DrPH Prescription Drug Data: Advantages, Availability, and Access FINANCIAL DISCLOSURE: Grants/Research Support: NIH, AHRQ UNLABELED/UNAPPROVED USES
More informationAn Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit. LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center
An Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center 1 TRICARE Eligible Beneficiaries Monthly Average, FY08 Retirees & Family
More informationCNODES: A Canadian Initiative
CNODES: A Canadian Initiative Samy Suissa Lady Davis Institute, Jewish General Hospital McGill University Montreal, Canada PROTECT Conference, EMA, London, 19 February, 2015 PROVINCE OF QUEBEC, CANADA
More informationArkansas Prescription Monitoring Program
Arkansas Prescription Monitoring Program ONE YEAR UPDATE Scott Pace, Pharm.D., Esq. Special Thanks Thanks to Denise Robertson at the Arkansas Department of Health for supplying the PMP data for this presentation
More informationOffice of the Auditor General Portage Avenue Winnipeg, Manitoba R3C 0C4
Office of the Auditor General 500-330 Portage Avenue Winnipeg, Manitoba R3C 0C4 April 2006 The Honourable George Hickes Speaker of the House Room 244, Legislative Building Winnipeg, Manitoba R3C 0V8 Dear
More informationHTH Page 1
. Page 1 Page 2 HTH-2014- Page 3 Page 4 Page 5 HTH-2 4 0 162 ge 6 Page 7 Page 8 Page 9 Page 10 HTH 2014-00162 Page 11 Page 12 Page 13 Page 14 H H 201 001 2 Pag 1 Page 16 Page 17 Page 18 Page 19 Page 20
More informationJustifying New Oncology Pharmacist Positions
Faculty Disclosures Justifying New Oncology Pharmacist Positions I will not be discussing off-label uses of any medications I am on the speaker s bureau for Millenium Pharmaceuticals and am a paid consultant
More informationChronic Disease and Aging: Health Policy Implications
Chronic Disease and Aging: Health Policy Implications Penny Ballem MD FRCP Clinical Professor of Medicine University of British Columbia Former Deputy Minister of Health, BC Aging and Chronic Disease Context
More informationOrgan Donation Breakthrough Collaborative Institute of Medicine
Organ Donation Breakthrough Collaborative Institute of Medicine June 20, 2005 Jade Perdue, M.P.A Department of Health and Human Services Health Resources and Services Administration Healthcare Systems
More informationIn Australia, brand substitution of
Pharmaceutical brand substitution in Australia are there multiple switches per prescription? Abstract Background: In Australia, brand substitution by pharmacists has been possible since 1994. There is
More informationAn Overview of a Provincial Appropriateness of Care Initiative: A Provincial Collaborative Supporting Appropriate, Affordable, and Accessible Care
An Overview of a Provincial Appropriateness of Care Initiative: A Provincial Collaborative Supporting Appropriate, Affordable, and Accessible Care John G. Abbott Deputy Minister, Department of Health and
More informationFAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)?
FAQs about Provider Profiles on Breast Cancer Screenings (Mammography) Q: Who receives a profile on breast cancer screenings (mammograms)? A: We send letters and/or profiles to PCPs with female members
More informationCPhA PRE-BUDGET CONSULTATION BRIEF Prescriptions for a healthy and productive Canada
CPhA PRE-BUDGET CONSULTATION BRIEF 2018 Prescriptions for a healthy and productive Canada Introduction On behalf of the Canadian Pharmacists Association (CPhA) and Canada s 40,000 pharmacists, we are pleased
More informationExecutive Summary. Classes Under Review: Analysis:
Outcome Report on MHQAC Edits Classes Under Review: Analysis: Atypical Antipsychotics, SSRIs, SNRIs, Antianxietals, Hypnotics, and Drugs to Treat ADD/ADHD Utilization and Cost Trends: Pre and Post Implementation
More informationEvaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration
Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Melissa LD Christopher, PharmD National Director Academic Detailing Program Office
More informationPrescription Switching and Reduced LDL-C Goal Attainment
Prescription Switching and Reduced LDL-C Goal Attainment JoAnne M. Foody, MD, FACC, FAHA Brigham and Women's Hospital, Boston, MA Disclosures Consultant for Merck and Pfizer Why Address Adherence? Increasing
More informationAbout CBME/CBD Susan Glover Takahashi, Lisa St. Amant, Amy Wong,
About CBME/CBD Susan Glover Takahashi, Director, EIG, PGME Lisa St. Amant, Education Integration Group (EIG), PGME Amy Wong, Education Integration Group (EIG), PGME Disclosure of Commercial Support This
More information4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP
New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6
More informationBC Methadone Maintenance System
BC Methadone Maintenance System Performance Measures 211/212 Office of the Provincial Health Officer With contributions by: Pharmaceutical Services Division & Population and Public Health Division British
More informationImpact of National Guidance for Drug Prescribing for Dentistry
Impact of National Guidance for Drug Prescribing for Dentistry Samantha Rutherford Jan Clarkson, Doug Stirling, Linda Young, Paula Elouafkaoui, Anna Templeton, Craig Ramsay on behalf of the TRiaDS methodology
More informationCost-Effectiveness of Lung Volume Reduction Surgery
Cost-Effectiveness of Lung Volume Reduction Surgery The Health Industry Forum October 24, 2007 - Washington DC The National Emphysema Treatment Trial National Emphysema Treatment Trial (NETT) Multicenter,
More informationThe Opioid Addiction Emergency In Virginia June 8, 2017
The Opioid Addiction Emergency In Virginia June 8, 2017 Marissa J. Levine, MD MPH State Health Commissioner Virginia Department of Health Chronic Disease of Addiction Definition: A primary, chronic disease
More informationA1. Does your government have a formal, written diabetes policy or strategy?
Survey of Diabetes Programs and Services in Canada Canadian Diabetes Association Diabetes Progress Report A1. Does your government have a formal, written diabetes policy or strategy? Yes. In October 2002,
More informationCity of Vancouver s Response to the Opioid Crisis Fire Chief Darrell Reid Vancouver Fire & Rescue Services (VF&RS)
City of Vancouver s Response to the Opioid Crisis Fire Chief Darrell Reid Vancouver Fire & Rescue Services (VF&RS) Vancouver Vancouver Fire Rescue Services Opioid Crisis Background Crisis Overview April
More informationRe: Docket No. FDA-2009-N-0294 Regulation of Tobacco Products; Request for Comments
VIA Electronic Submission to http://www.regulations.gov September 29, 2009 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Docket
More informationDr. Steve Ligertwood Dr. Roderick Tukker Dr. David Wilton
Dr. Steve Ligertwood Hospitalist Royal Columbian Hospital Regional Department Head-Hospitalist for Fraser Health Authority Project Lead BC Hospitalist VTE Collaborative Clinical Instructor, UBC School
More informationFigure 1: Quantity Dispensed/100 Members (Ambien and Sonata on left axis)
Sedative Hypnotic Quantity Limit Policy Impact Analysis Effective 12/6/2 OMAP implemented a 15 tablet per 3 day quantity limit on non-barbiturate sedative hypnotics for FFS patients. This policy was made
More informationMAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS
MAXIMUM ALLOWABLE COST POLICY CHANGES DECEMBER 5, 2016 QUESTIONS AND ANSWERS The November 22, 2016 Mid-Year Financial Report referred to changes to drug coverage under the Saskatchewan Drug Plan. What
More informationNorth Dakota Board of Pharmacy
North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives
More informationCITIZEN BRIEF MAKING FAIR AND SUSTAINABLE DECISIONS ABOUT FUNDING FOR CANCER DRUGS IN CANADA
CITIZEN BRIEF MAKING FAIR AND SUSTAINABLE DECISIONS ABOUT FUNDING FOR CANCER DRUGS IN CANADA 29-30 OCTOBER 2016 Making Fair and Sustainable Decisions about Funding for Cancer Drugs in Canada McMaster Health
More informationStudy Exposures, Outcomes:
GSK Medicine: Coreg IR, Coreg CR, and InnoPran Study No.: WWE111944/WEUSRTP3149 Title: A nested case-control study of the association between Coreg IR and Coreg CR and hypersensitivity reactions: anaphylactic
More informationTransforming Care for the Elderly
Transforming Care for the Elderly Session 2: Engaging Pharmacists & Interdisciplinary Care Teams to Improve Prescribing of Antipsychotics & to Reduce Polypharmacy January 11, 2017 3 @cfhi_fcass Welcome
More informationSADAG submission to the Competition Commission: Market Inquiry into the Private Healthcare Sector
THE SOUTH AFRICAN DEPRESSION AND ANXIETY GROUP NPO 013-085 Reg. No. 2000/025903/08 P O Box 652548 Benmore 2010 Tel: +27 11 234 4870 Fax: +27 11 234 8182 office@anxiety.org.za www.sadag.org SADAG submission
More informationMeasure Up/Pressure Down Medical Group Success
Measure Up/Pressure Down Medical Group Success Deborah A. Molina, MPA, MBA Manager, Quality Jamie L. Reedy, MD, MPH Medical Director, Population Health Laura Balsamini, Pharm D, BCPS Director, Pharmacy
More informationRegion of Waterloo Public Health and Emergency Services Infectious Diseases, Dental, and Sexual Health
Region of Waterloo Public Health and Emergency Services Infectious Diseases, Dental, and Sexual Health To: Chair Geoff Lorentz and Members of the Community Services Committee Date: March 2, 218 File Code:
More informationReview of Controlled Drugs and Substances Act
Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A
More informationBC PharmaCare Newsletter
BC PharmaCare ewsletter August 24, 2010 Edition 10-009 Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Pharmacy Services
More informationBC Methadone Maintenance System: Performance Measures 2011/2012 Appendix A: Report Figures and Data
BC Methadone Maintenance System: Performance Measures 2011/2012 Pharmaceutical Services Division & Population and Public Health Division British Columbia Ministry of Health February 2013 You may download
More informationAlberta Health. Seasonal Influenza in Alberta Season. Analytics and Performance Reporting Branch
Alberta Health Seasonal Influenza in Alberta 2015-2016 Season Analytics and Performance Reporting Branch August 2016 For more information contact: Analytics and Performance Reporting Branch Health Standards,
More informationOSCR ANNUAL REVIEW Charities you can trust and that provide public benefit
OSCR ANNUAL REVIEW -14 Charities you can trust and that provide public benefit OUR IMPACT We have had another busy and productive year supporting and monitoring the country s 23,700 charities. Our volume
More informationPharmacy Trends and Management Opportunities. Kerry Bendel, R.Ph. Director of Pharmacy Medica
Pharmacy Trends and Management Opportunities Kerry Bendel, R.Ph. Director of Pharmacy Medica September 14, 20 1 Agenda Pharmacy Trend Experience Trend Drivers and Management Opportunities Call to Action
More informationSleep Market Panel. Results for June 2015
Sleep Market Panel Results for June 2015 Notes: o This is a monthly trending report of panel member data along with additional analysis by: Sleep labs affiliated with Hospitals vs. Independent Labs o Hospital
More informationTouchpoints Prior to Opioid Overdose Death
Touchpoints Prior to Opioid Overdose Death 7th Annual BU-CTSI Translational Science Symposium May 3, 2018 Marc Larochelle, MD, MPH Assistant Professor of Medicine Boston Medical Center and Boston University
More informationPrescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study
Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study Presented By: Scott McKibbin Special Advocate For Prescription Drugs State Of Illinois
More informationMinistry of Health and Long-Term Care. Presentation to the CPSO Methadone Prescribers Conference
Ministry of Health and Long-Term Care Presentation to the CPSO Methadone Prescribers Conference November 9, 2012 Overview Minister s Expert Working Group on Narcotic Addiction OxyNEO and OxyContin: Changes
More informationTools for Targeting High Risk Patients in Your Practice. Statement of Disclosure
Tools for Targeting High Risk Patients in Your Practice Joseph Vande Griend, PharmD, BCPS, CGP Assistant Professor, University of Colorado Departments of Clinical Pharmacy and Family Medicine Skaggs School
More informationObjectives. Quality Improvement: Learning Collaboratives & Pharmacist involvement
Quality Improvement: Learning Collaboratives & Pharmacist involvement Jennifer Lake, PharmD Ontario FHT Pharmacist Conf 10 Nov 2009 Objectives To review the goals and objectives of the Learning Collaboratives
More informationPositive Living Conference
Positive Living Conference Ft. Walton Beach, Thomas Liberti Chief, Bureau of HIV/AIDS Department of Health March 11, 2011 Tallahassee, 1 The Epidemic in, 2010 60% White Population: 18.8 million (4 th 16%
More informationBC Confederation of Parent Advisory Councils
BC Confederation of Parent Advisory Councils Tab 20 Page 1 Tab 20 ~ BC Confederation of Parent Advisory Councils In this Tab 20, you will find Purposes of BCCPAC Page 2 About BCCPAC Page 3 Membership Page
More informationPolicy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
More informationPharmaceutical System in the UK
Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose
More informationComparison of tiered formularies and reference pricing policies: a systematic review
Comparison of tiered formularies and reference pricing policies: a systematic review Steve Morgan, Gillian Hanley, Devon Greyson ABSTRACT Objectives: To synthesize methodologically comparable evidence
More information- Description, Objectives, Operational Framework
2 1. CNCD - Overview (significance, causes, burden) 2. CDAP - Description, Objectives, Operational Framework 3. Research Findings of Study on CDAP - Research Objectives and Methodology - Limitations and
More informationImprovement Initiative for Patient Falls Susan Moffatt-Bruce, B.Sc. (Hon), M.D., Ph.D., FRCS(C), FACS, MBOE, Chief Quality and Patient Safety Officer
Improvement Initiative for Patient Falls Susan Moffatt-Bruce, B.Sc. (Hon), M.D., Ph.D., FRCS(C), FACS, MBOE, Chief Quality and Patient Safety Officer Amy M. Knupp MSN, RN, CNS, CPPS, Director of Nursing
More informationReducing Falls Causing Harm in Older People with Dementia. Professor Tony Elliott South Staffordshire and Shropshire FT
Reducing Falls Causing Harm in Older People with Dementia Professor Tony Elliott South Staffordshire and Shropshire FT Project Site 16 bedded Dementia Inpatient Unit Acute admissions from home, DGHs or
More informationUsing Decision Support to Promote Value Based Prescribing
Using Decision Support to Promote Value Based Prescribing Session 218, February 14, 2019 Adam Szerencsy, DO Medical Director, Ambulatory Informatics NYU Langone Health 1 Conflict of Interest Adam Szerencsy,
More informationDoctors, Nurses... and pharmacists - why this threesome works. Vanessa Brown Brendan Duck RNZCGP GPCME 2014
Doctors, Nurses... and pharmacists - why this threesome works. Vanessa Brown Brendan Duck RNZCGP GPCME 2014 What is a clinical pharmacist? Specialist Pharmacist Practitioner Post Graduate education and/or
More information2017/ /20 SERVICE PLAN
SERVICE PLAN September 2017 For more information on the Legal Services Society, contact: Mark Benton, QC Chief Executive Officer Legal Services Society 400 510 Burrard Street Vancouver, BC V6C 3A8 604-601-6000
More informationCanadian Diabetes Association 2013
Spring 2014 Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align to the guidelines? Canadian Diabetes Association 2013 clinical practice guidelines - Do claims data align
More informationBuilding Capacity for Smoking Cessation Treatment Within Primary Care Teams
Building Capacity for Smoking Cessation Treatment Within Primary Care Teams Justine Mascarenhas, MSc and Janine Fitzpatrick, MCogSc Investigators: Dr. Peter Selby and Dr. Laurie Zawertailo STOP Program,
More informationMETHADONE PROGRAM ANNUAL REPORT 2012 AND BUSINESS PLAN 2013
METHADONE PROGRAM ANNUAL REPORT 2012 AND BUSINESS PLAN 2013 May 2013 P a g e 2 Table of Contents ANNUAL REPORT 2012... 3 BUSINESS PLAN 2013... 6 APPENDICES A - Methadone Monthly Patient Statistics 2012...
More informationANNUAL REPORT
ANNUAL REPORT - 2015 New Hampshire Prescription Drug Monitoring Program Report for July 1, 2014 June 30, 2015 Published October 2015 Table of Contents Executive Summary... 3-4 NH PDMP Background Information
More informationReducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital
Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital Dawn Waddell, PharmD, BCPS Clinical Pharmacy Manager Lisa Kingdon, PharmD, BCPS Clinical Pharmacy Specialist Dawn Waddell
More informationLike others here today, we are very conflicted on the FDA s proposal on behind-thecounter medications, but thank you for raising the issue.
Statement of Consumers Union William Vaughan, Senior Policy Analyst before the US Food and Drug Administration Public Meeting on Behind the Counter Availability of Drugs November 14, 2007 Consumers Union
More informationOrthopaedic Section of the APTA Grant Program Annual Progress Report Form
Orthopaedic Section of the APTA Grant Program Annual Progress Report Form Date: 9/21/2015 Name of Investigators: Name of Grant: Shane McClinton, Timothy Flynn, Bryan Heiderscheit Comparison of Usual Podiatric
More informationKENT BISHOP M.D. ProMedica Chief Experience Officer President Women s Service Line
KENT BISHOP M.D. ProMedica Chief Experience Officer President Women s Service Line 1 WHEN A VISION TAKES SHAPE. 2 3 4 Modern Facilities Clinical Service Lines Quality/ Safety Mental Health Clinical Research
More informationUnderstanding the Value of Generic Drugs
Understanding the Value of Generic Drugs Generic drugs can help you get the most out of your health care budget. 05.02.306.1 (8/05) Many people believe that when something costs more, it must be of higher
More informationMichael J. Negrete, PharmD Chief Executive Officer
Making the Most of Your Medications Michael J. Negrete, PharmD Chief Executive Officer 2 Drivers of Increasing Drug Spending Three main factors: Price Increases 24% Drug Mix 28% 3 Utilization 48% Aging
More informationYour Prescription Card. Your guide for savings.
CVS Caremark 620 Epsilon Drive Pittsburgh, PA 15238 4750-_PM 9501 E. Shea Blvd SCOTTSDALE, AZ 85260 Your Prescription Card. Your guide for savings. Dear Plan Member, Welcome to your new benefits. Attached
More informationSTRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS.
STRENGTHENING THE COORDINATION, DELIVERY AND MONITORING OF HIV AND AIDS SERVICES IN MALAWI THROUGH FAITH-BASED INSTITUTIONS. Acknowledgements This project was fully funded by Center For Disease Control
More information2017/ /20 SERVICE PLAN
Ministry of Mental Health and Addictions 2017/18 2019/20 SERVICE PLAN September 2017 For more information on the British Columbia Ministry of Mental Health and Addictions contact: Ministry of Mental Health
More informationLarge trials vs observational studies in assessing benefit and harm: the example of aprotinin
Large trials vs observational studies in assessing benefit and harm: the example of aprotinin Dean A. Fergusson, MHA, PhD Senior Scientist and Associate Director, Clinical Epidemiology Program, Ottawa
More informationKansas EMS Naloxone (Narcan) Administration
Kansas EMS Naloxone (Narcan) Administration Executive Summary Kansas Board of Emergency Medical Services August 217 The following pages denote an ongoing trending of naloxone administration by Kansas Emergency
More informationMed Wreck to Med Rec How medication reconciliation can (should) change your practice!
Med Wreck to Med Rec How medication reconciliation can (should) change your practice! Dan Martinusen BSc(Pharm),ACPR, PharmD Chair, BCPRA Pharmacy & Formulary Committee Marianna Leung B Sc(Pharm), ACPR,
More informationBudnitz DS et al. NEJM Background
Camille P. Vaughan, MD, MS Associate Section Chief for Research, Geriatrics & Gerontology Investigator, Birmingham/Atlanta VA GRECC Assistant Professor Division of General Medicine & Geriatrics Emory University
More informationThe CIDRZ Experience: use of data to understand patient outcomes and guide program implementation 07 January 2010
The CIDRZ Experience: use of data to understand patient outcomes and guide program implementation 07 January 2010 Dr C Bolton Moore Deputy Medical Director CIDRZ Ministry of Health Zambia University of
More informationBibliographic Information Service of Health Sciences in Japan
MLA 09 Annual Meeting and Exhibition; Honolulu, Hawaii May 19th Issues in Japanese Health Sciences Librarianship Bibliographic Information Service of Health Sciences in Japan M. IKUSAKI, M. MATSUDA, K.
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationCurators of the University of Missouri - Combined January 01, 2013 through December 31, 2013 Cost Management Report
Cost Management Report Program Design Specifics Standard Claims Management SAVINGS CATEGORIES SAVINGS RESULTS % OF NET SUBMITTED DOLLARS % OF PAID DOLLARS Deductible Applied $1,296,627 5.68% 9.78% Patient
More informationAccess to newly licensed medicines. Scottish Medicines Consortium
Access to newly licensed medicines Scottish Medicines Consortium Modifiers The Committee has previously been provided with information about why the SMC uses modifiers in its appraisal process and also
More informationPalliative Care in Ontario and the Declaration of Partnership and Commitment to Action
Palliative Care in Ontario and the Declaration of Partnership and Commitment to Action Canadian Association of Health Services and Policy Research Conference May 2014 Denise Marshall, MD, CCFP, FCFP Palliative
More information2:15 3 pm Harold DeMonaco, Director, Innovation Support Center at Massachusetts General Hospital. News Media and New Treatments
2:15 3 pm Harold DeMonaco, Director, Innovation Support Center at Massachusetts General Hospital News Media and New Treatments As consumers become more involved in their own care choices, the need for
More informationThe Sutter Medical Network: Nearly 5,000 physicians focused on care around the patient.
The Sutter Medical Network: Nearly 5,000 physicians focused on care around the patient. 1 About the Sutter Medical Network Our Mission The Sutter Medical Network provides a leadership role in the development
More informationAlberta Health. Seasonal Influenza in Alberta. 2016/2017 Season. Analytics and Performance Reporting Branch
Alberta Health Seasonal Influenza in Alberta 2016/2017 Season Analytics and Performance Reporting Branch September 2017 For more information contact: Analytics and Performance Reporting Branch Health Standards,
More informationMinistry of Children and Youth Services. Follow-up to VFM Section 3.01, 2013 Annual Report RECOMMENDATION STATUS OVERVIEW
Chapter 4 Section 4.01 Ministry of Children and Youth Services Autism Services and Supports for Children Follow-up to VFM Section 3.01, 2013 Annual Report RECOMMENDATION STATUS OVERVIEW # of Status of
More informationFaster Cancer Treatment: Using a health target as the platform for delivering sustainable system changes
Faster Cancer Treatment: Using a health target as the platform for delivering sustainable system changes Organisation Name: Ko Awatea, Counties Manukau Health Presenter: Bob Diepeveen HRT 1520 Innovations
More informationClinical risk management in community pharmacy - Henk Buurma SUMMARY
SUMMARY Summary This thesis starts with an introduction (Chapter 1) in which an overview of the recent history of community pharmacy practice is presented, and in which we elaborate on the evolving role
More informationRxVACCINATE: A National Education and Practice Support Initiative to Increase Pharmacist Administered Pneumococcal Vaccinations.
RxVACCINATE: A National Education and Practice Support Initiative to Increase Pharmacist Administered Pneumococcal Vaccinations. Pfizer Grant 45130: LOI Pneumococcal Disease Prevention Grant ID: 45130
More informationCOMMITMENT TO A TOBACCO ENDGAME IN ONTARIO
COMMITMENT TO A TOBACCO ENDGAME IN ONTARIO Our Ask That the Ontario government: Renew their commitment to achieving the lowest smoking rate in Canada Align the Smoke Free Ontario Strategy with the proposed
More informationThis document was created on 07 January 2005 and has been printed from
1 Spontaneous Adverse Event Reporting Information Introduction This document provides information regarding spontaneous adverse event reports received concerning patients taking rosuvastatin, which relates
More informationLeeds West CCG Paediatric asthma project. January 2015-January 2017
Leeds West CCG Paediatric asthma project. January 2015-January 2017 Aims to raise asthma awareness improve care reduce emergency attendances and unplanned admissions to secondary care for children with
More information